Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18217
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChia, Puey Ling-
dc.contributor.authorChiang, K-
dc.contributor.authorSnyder, R-
dc.contributor.authorDowling, A-
dc.date2017-03-12-
dc.date.accessioned2018-08-23T06:36:28Z-
dc.date.available2018-08-23T06:36:28Z-
dc.date.issued2018-06-
dc.identifier.citationJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2018; 24(4): 264-271-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/18217-
dc.description.abstractBackground Anthracycline-based chemotherapy is used in many malignancies. Current recommendations by several groups suggest cardiac monitoring prior to and during anthracycline therapy. We aim to review the usefulness of baseline cardiac screening for left ventricular ejection fraction to assess if it had any impact on chemotherapy decisions in patients to be treated with anthracycline-based regimens or any beneficial effect upon outcomes. Methods We conducted a retrospective three-year audit of cancer patients who underwent GBPS prior to anthracycline (doxorubicin) chemotherapy. Subjects were identified via records from the Department of Nuclear Medicine. Pharmacy dispensing records identified those who received doxorubicin. Patient demographics, cancer type, cardiac risk factors, GBPS ejection fraction (EF), and cumulative anthracycline dose were collected. Results From 1 August 2009 to 31 July 2012, 179 patients underwent GBPS pre-doxorubicin chemotherapy. The mean age was 59 years (range 21-89 years), with 51% being males. Only two patients (1.1%) had an abnormal EF < 50%, while 33 patients (18%) had an EF 51-59% and 144 patients (80%) had EF ≥ 60%. The two patients with reduced baseline EF still received anthracycline-based chemotherapy. All 135 patients without any known cardiovascular risk factors had normal EFs. The total number of patients who received anthracycline chemotherapy during the same period was 207. Thus 28 patients (13%) commenced anthracycline without a prior GBPS. Conclusion Only 1.1% of the screened patients had EF < 50%. These two patients still received doxorubicin chemotherapy despite a compromised EF, as their treating clinicians believed that the benefits of chemotherapy outweighed the risk of potential cardiac toxicity. Our audit questions the practice of routine cardiac evaluation pre-anthracycline screening with GBPS. We propose that routine screening only be requested if cardiac risk factors are present.-
dc.language.isoeng-
dc.subjectAnthracycline-
dc.subjectcardiac gated blood pool scan-
dc.subjectcardiac toxicity-
dc.subjectdoxorubicin-
dc.titleThe utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity.-
dc.typeJournal Article-
dc.identifier.journaltitleJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners-
dc.identifier.affiliationDepartment of Medical Oncology, St Vincent's Hospital Melbourne, Melbourne, Australia-
dc.identifier.affiliationDepartment of Medical Oncology, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Pharmacy, St Vincent's Hospital Melbourne, Australia-
dc.identifier.doi10.1177/1078155217697487-
dc.identifier.pubmedid29284360-
dc.type.austinJournal Article-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Jan 27, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.